Compare TYG & FTRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TYG | FTRE |
|---|---|---|
| Founded | 2003 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Medical Specialities |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.3B |
| IPO Year | 2003 | 2023 |
| Metric | TYG | FTRE |
|---|---|---|
| Price | $43.12 | $19.79 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $14.06 |
| AVG Volume (30 Days) | 108.8K | ★ 970.2K |
| Earning Date | 05-04-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.71% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $2,723,400,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $3.09 |
| P/E Ratio | $52.62 | ★ N/A |
| Revenue Growth | N/A | ★ 1.00 |
| 52 Week Low | $40.35 | $8.31 |
| 52 Week High | $51.18 | $21.39 |
| Indicator | TYG | FTRE |
|---|---|---|
| Relative Strength Index (RSI) | 57.37 | 45.16 |
| Support Level | $42.23 | $17.37 |
| Resistance Level | $45.31 | $18.13 |
| Average True Range (ATR) | 0.68 | 0.77 |
| MACD | 0.06 | -0.13 |
| Stochastic Oscillator | 75.54 | 40.95 |
Tortoise Energy Infrastructure Corp seeks to provide a high level of current income to stockholders. It invests in fixed-income and dividend-paying equity securities of power and energy infrastructure companies that provide stable and defensive characteristics throughout economic cycles.
Fortrea is a global, late-stage contract research organization that provides comprehensive phase 1 through phase 4 clinical trial management, clinical pharmacology, and patient access solutions. The company works with emerging and large biopharma, medical device, and diagnostic companies to run their clinical trials as a functional-service provider, full-service provider, and offers hybrid trials. In 2023, Fortrea was formed as an independent, publicly traded company after Labcorp spun off its clinical development business, which it acquired via its purchase of Covance in 2015 for $6.1 billion.